IntellxxDNA

Diagnostic

Empowering clinicians with genomics-based insights to improve patient outcomes and personalize care.

Services
  • Clinical Decision Support Tool
  • Health Focused Genomic Reports
Location Austin, Texas
About

IntellxxDNA

In an era where precision is paramount, IntellxxDNA is revolutionizing the way physicians approach healthcare decisions. Unlike traditional genomics tools that focus solely on pharmacogenomics, cancer genomics, or rare diseases, IntellxxDNA provides a comprehensive solution for managing multifactorial chronic conditions such as heart disease, diabetes, cognitive decline, mental health issues, and autism, among others. By enabling physicians to identify and address the root causes of diseases, IntellxxDNA not only improves prevention and treatment but also reduces the cost of healthcare.

What sets IntellxxDNA apart is its ability to make genomics truly actionable. IntellxxDNA empowers physicians to implement personalized, precise treatment plans by reporting on gene variants with well-understood functions and pairing them with targeted potential interventions, including diet, lifestyle modifications, supplements and medications. This innovative approach is already being utilized by top physicians across the US to enhance patient outcomes and satisfaction and is being utilized in three IRB-approved trials focused on improving outcomes in cognitive decline and children with complex illness.

Unlock exclusive discounts and offers from IntellxxDNA and other trusted partners with an SSRP Pro Membership.
What People Say

Testimonials

I wanted to add my two cents worth in support of IntellxxDNA and Dr Sharon Hausman-Cohen MD, et al, as a Trusted Partner with SSRP. I have used different genetics companies in my practices since 2010, starting with Kendal Stewart, MD, working the actionable SNP’s to improve health in my patients care. Over the years I never really found a platform that provided relevant clinical guidance with all of the evidence backed research at your fingertips prior to engaging with Dr Hausman-Cohen and IntellxxDNA. I was so impressed I recommend this company to Dr Seeds as one of the missing pieces in the Cellular Medicine puzzle. Dr Seeds got back to me and expressed is thanks for introducing Dr Hausman-Cohen. He said that she was the first doctor that could answer all his questions and provide a workable clinical platform to make the complex useful and improve the clinical success that SSRP Members are looking for. I have attended their monthly case studies, worked with their trainers on my complex patients and can say their support is excellent, the guidance is clinically valuable and adding IntellxxDNA to the Trusted Partners will be a valuable benefit for our Membership.

Kenton Crowley, Pharm.D., ABAAHP, FAARFM, CEO, President Palliative Care Consultants, LLC.; Crowley Consultants, Inc.
Network with our partners

Upcoming Events

View Upcoming Events
EVENT
Grand Rounds
December 4 - 5, 2026

Grand Rounds

Coming Soon
RESOURCES

Join us in breaking down the latest research live.

VIEW ALL
PODCAST
Redox Revolution
Sep 22, 2026
Ep.78 – Do Peptides Cause Cancer? The Risks, The Myths, And The Evidence
Ep.78 – Do Peptides Cause Cancer? The Risks, The Myths, And The Evidence

In this episode, Dr. Seeds addresses the many misunderstandings related to peptides and cancer.

Cellular Medicine Foundations · Peptides & Protocols
Peptide Therapy Certification 2026
The SSRP Peptide Therapy Certification course gives clinicians, researchers, and other healthcare providers a working method for applying Cellular Medicine principles to patient care through clinical peptide therapy. Across 19 faculty-led lessons, Dr. William Seeds and SSRP faculty, including Siobhan...
19 Lessons
15 hrs 43 min
View Course
VIDEO
Cellular Medicine Mondays
Sep 21, 2026
Ep. 106 - Peptide Support After Transplant: What to Consider First
Preview only
Dissecting Protocols – Episode 106

Peptide Support After Transplant: What to Consider First

Dr. Seeds explores how to protect graft integrity and identify the right cellular targets before considering peptide support in a patient six years post liver transplant.

Preview Only — Become a member for full access
SSRP Institute Sep 14, 2026
In Case You Missed it: FDA Approves Mounjaro (tirzepatide) for CVD
HEADLINE SCIENCE [Sept 14, 2026] – On August 28, 2026, the FDA expanded the indication for Mounjaro (tirzepatide), approving the dual GIP/GLP-1 receptor agonist to reduce the risk of major adverse cardiovascular events—including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke—in adults with type 2 diabetes at high cardiovascular risk. The decision makes tirzepatide the […]
READ NEWS
EVENT
Certification
September 10 - 11, 2027
Peptide Therapy Certification 2027
Four Seasons Resort Orlando at Walt Disney World, FL
COMING SOON
Certification
Peptide Therapy Certification 2027
COMING SOON
EVENT
World Congress
June 17 - 19, 2027
Peptide World Congress 2027
Arizona Biltmore, Phoenix, AZ
COMING SOON
World Congress
Peptide World Congress 2027
COMING SOON
EVENT
Mastermind
February 15 - 19, 2027
Fellowship Mastermind Summit 2027
Gansevoort Meatpacking NYC, New York, NY
COMING SOON
Mastermind
Fellowship Mastermind Summit 2027
COMING SOON
EVENT
Grand Rounds
December 4 - 5, 2026
Grand Rounds
Four Seasons Resort and Residences Vail
COMING SOON
Grand Rounds
Grand Rounds
COMING SOON
SSRP Institute Aug 27, 2026
Rasonque: An FDA-Approved Drug to Treat Pancreatic Cancer
HEADLINE SCIENCE [August 27, 2026] – The Food and Drug Administration on Wednesday approved daraxonrasib, sold as Rasonque, for adults with metastatic pancreatic adenocarcinoma, the most common form of pancreatic cancer and one long considered among the hardest to treat. The once-daily tablet, developed by Revolution Medicines, is the first targeted therapy approved for the […]
READ NEWS
SSRP Institute Aug 21, 2026
Alpha-Gal Syndrome: An Update on Incidence Rate by the CDC
HEADLINE SCIENCE [August 21, 2026] – JAMA recently published a report about the incidence rate of alpha-gal syndrome, which is a serious allergic reaction to a sugar molecule called alpha-gal, which is found in most mammals. It is typically transmitted through a bite from a Lone Star tick or other tick species that injects the […]
READ NEWS
IntellxxDNA Aug 12, 2026
SSRP Institute Welcomes IntellxxDNA as New Trusted Partner
PARTNER ANNOUNCEMENT WILLOUGHBY, Ohio, [August 12, 2026] — The SSRP Institute welcomes IntellxxDNA to its Trusted Partner Network following a nomination and internal vetting process, aligning with SSRP’s mission to advance science-first, education-driven clinical collaboration. IntellxxDNA provides clinicians with a structured genomic decision support platform that translates complex genetic data into clinically actionable insights. Using […]
READ NEWS
ARTICLE
William Seeds, MD
Aug 6, 2026
A Lipid at the Root of Mitochondrial Aging: Phosphatidylcholine, Methylation, and a Malleable Therapeutic Window
William Seeds, MD Aug 6, 2026
A Lipid at the Root of Mitochondrial Aging: Phosphatidylcholine, Methylation, and a Malleable Therapeutic Window
Mitochondrial dysfunction is one of the most firmly established hallmarks of aging, but the field has spent far more energy describing genetic causes of mitochondrial failure—mtDNA mutation, defective OXPHOS, impaired unfolded protein response—than the “natural” drivers that erode mitochondria during ordinary aging. As I discussed in my recent June Journal Club (as well as a […]
READ ARTICLE